W
WAVEMAN · COMPANY
MRNA · Moderna, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

MRNA

Moderna, Inc.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001682852
FORM 144 · 4☆ WATCH
INSIDER NET · 180D
-$39.0M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
403
13F, latest reported quarter
REVENUE GROWTH
-39.9%
XBRL, annual
NET MARGIN
-145.2%
CONVERSIONS · 180D
39
codes C/M, not in net · $17.9M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$39.0M over 180 days
-$35.5M over 90 days
below 93% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
403 funds added or opened last quarter
more than 95% of Pharma & Biotech
REVENUE
-39.9% year over year
below 80% of Pharma & Biotech
MARGIN
-145.2% net margin
below 69% of Pharma & Biotech
BUYBACKS
$2.0M repurchased, FY to 2025-12-31
below 84% of Pharma & Biotech
SHORT
12.5% of shares outstanding short · 10.2 days to cover · settled 2026-07-31
more than 85% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$39.0M across 5 people in 180 days.
403 funds added or opened positions in the latest 13F quarter, of 787 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +523.4%
+523.4%12M
-8%+202%+411%+621%2025-092025-102025-122026-032026-052026-072026-09 2026-08-05 · Bancel Stephane sold $11.0M2026-08-05 · Bancel Stephane sold $8.3M2026-02-23 · Hoge Stephen sold $7.8M2026-08-05 · Bancel Stephane sold $7.1M2026-07-15 · Hoge Stephen sold $3.6M2026-06-15 · Hoge Stephen sold $2.7M2026-05-15 · Hoge Stephen sold $2.6M2026-08-05 · Bancel Stephane sold $2.3M2026-03-02 · Klinger Shannon Thyme sold $726.0K2025-12-11 · AFEYAN NOUBAR sold $703.4K2026-09-01 · Klinger Shannon Thyme sold $485.8K2026-05-21 · AFEYAN NOUBAR sold $433.9K2026-05-01 · Hussain Abbas sold $265.0K2026-06-04 · Klinger Shannon Thyme sold $173.6K2025-12-09 · Hussain Abbas sold $13.9K2026-09-01 · Klinger Shannon Thyme filed to sell $485.8K2026-08-05 · Bancel Stephane filed to sell $29.0M2026-07-15 · Hoge Stephen filed to sell $3.6M2026-06-18 · SAGAN PAUL filed to sell $1.7M
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $39.0M sold by insiders over 180 days, 403 funds added last quarter, $34.7M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXREGNLLYALNYELFCITRMDGLDNAVRTXNUVLINSM
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Moderna, Inc. insiders sold a net $39.0M of stock across 1,459 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
Klinger Shannon Thyme
Chief Legal Officer
SELL
2026-09-01
3,471.0
$485.8K
Bancel Stephane
Chief Executive Officer
SELL
2026-08-05
147,473.0
$8.3M
Bancel Stephane
Chief Executive Officer
SELL
2026-08-05
124,838.0
$7.1M
Bancel Stephane
Chief Executive Officer
SELL
2026-08-05
39,891.0
$2.3M
Bancel Stephane
Chief Executive Officer
SELL
2026-08-05
187,044.0
$11.0M
1,459 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 1,454 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
FMR LLC
51,859,891.0 sh
$3.6B
BlackRock, Inc.
30,599,409.0 sh
$2.1B
VANGUARD CAPITAL MANAGEMENT LLC
23,208,792.0 sh
$1.6B
Capital World Investors
22,276,996.0 sh
$1.6B
BAILLIE GIFFORD & CO
18,206,778.0 sh
$1.3B
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Klinger Shannon Thyme
FILED 2026-09-01
$485.8K
Bancel Stephane
FILED 2026-08-05
$29.0M
Hoge Stephen
FILED 2026-07-15
$3.6M
SAGAN PAUL
FILED 2026-06-18
$1.7M
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Global X Genomics & Biotechnology ETF
$4.1M POSITION · AS OF 2026-02-28
7.9%
iShares Genomics Immunology and Healthcare ETF
$10.1M POSITION · AS OF 2026-04-30
6.3%
First Trust NYSE Arca Biotechnology Index Fund
$119.4M POSITION · AS OF 2026-03-31
5.3%
VanEck Biotech ETF
$11.5M POSITION · AS OF 2026-03-31
3.1%
iShares Health Innovation Active ETF
$266.6K POSITION · AS OF 2026-04-30
2.6%
Fidelity Disruptive Medicine ETF
$1.6M POSITION · AS OF 2026-02-28
2.6%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Executive pay vs shareholder return · Mr. Bancel
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$19.9M
$15.8M
$9.8M
-72%
+20%
2024
$19.9M
$5.8M
$14.6M
-60%
-9%
2023
$17.1M
-$155.6M
$5.1M
-5%
-8%
2022
$19.4M
-$306.2M
$5.8M
+72%
-11%
2021
$18.2M
$793.0M
$8.3M
+143%
-1%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$1.9B$3.2B$6.8B$19.3B
OPERATING INCOME$-3.1B$-3.9B$-4.2B$9.4B
NET INCOME$-2.8B$-3.6B$-4.7B$8.4B
EPS (DILUTED)-7.26-9.28-12.3320.12
OPERATING CASH FLOW$-1.9B$-3.0B$-3.1B$5.0B
CASH$2.6B$1.9B$2.9B$3.2B
LONG-TERM DEBT$590.0M$0——
BUYBACKS$2.0M$0$1.2B$3.3B
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →